Schering/IBA set up UK PET (positron emission tomography) imaging radiotracer company:
This article was originally published in Clinica
Executive Summary
Schering AG's UK business, Schering Health Care, has teamed up with IBA of Belgium to form a new UK company for the supply of a positron emission tomography (PET) imaging radiotracer. UK Radiopharma will be the country's first commercially licensed supplier of F-18 fluodeoxyglucose (FDG), which it will sell as Flucis. Market launch is expected by 2005. Schering AG and IBA (which already sells FDG in the US) plan eventually to create a European network of FDG production sites. FDG is the most commonly used radioactive tracer used in PET imaging for cancer diagnosis and treatment monitoring.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.